Quarterly report
Open the filing on sec.gov
Bausch Health Companies Inc (BHC)
NYSE: BHC · Pharmaceutical Preparations · Quebec, QC · filing with the SEC since 1996
Grade5.3
◀ Past 5.2● Present 5.9▶ Future 4.7
The companyfiscal 2025, as filed
Revenue$10.27B+6.7%
Net income$120M+266.7%
Earnings per share$0.42+423.1%
Operating cash flow$1.40B-12.3%
Cash$1.31B+10.8%
Debt$20.59B+8.7%
Shareholders’ equity$377M+217.1%
Shares, diluted375.0M+1.9%
Return on equity31.8%
The recordfrom its filings
Filings in 202660
Newest filingOct 29 · 10-Q
Annual reportFeb 19, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$500,000
Insider buys, 12 months$0.00
Patents granted187
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $11.11BNet income -$828MCash from operations $2.21Bthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
The company now
Bausch Health reported third-quarter 2026 revenue of $2.94 billion on 28 October, up 10 percent from $2.68 billion a year earlier 1.
Net income attributable to the company was $436 million, against $179 million a year before 1.
Management said the part of the company outside Bausch + Lomb, its eye health arm, grew revenue and adjusted EBITDA (earnings before interest, taxes and other items) for a fourteenth straight quarter 1.
The Salix segment, home of the gut drug Xifaxan, led with revenue of $831 million, up 16 percent 1.
The company gave full-year 2026 revenue guidance of $10.975 billion to $11.175 billion for the whole company 1.
It also said it remains committed to evaluating all options for the value of its Bausch Health and Bausch + Lomb assets 1.
As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.
News
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.